Stifel Maintains Hold on Vertex Pharmaceuticals, Raises Price Target to $373
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Paul Matteis maintains a 'Hold' rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and raises the price target from $340 to $373.
November 07, 2023 | 3:14 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Stifel analyst maintains a 'Hold' rating on Vertex Pharmaceuticals and raises the price target from $340 to $373.
The news is directly about Vertex Pharmaceuticals. The 'Hold' rating suggests that the stock is expected to perform in line with the market or the sector in the next 12 months. The increase in price target indicates that the analyst sees potential for the stock's price to rise, but it's not a strong buy recommendation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100